Resources
45 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 9/28/2022 (updated 10/26/2023)
During the August 2022 RCORP Data Coordinator Calls, many of those who attended expressed interest in learning more about how to use GoogleForms to collect data from their consortium members and partners.
Posted 11/1/2022 (updated 10/26/2023)
During the September 2022 Data Coordinator meetings, many of those who attended expressed interest in learning more about how to use their RCORP data to create a data visualization. Below, you’ll find the recording and slides from the session, Creating Data Visualizations with RCORP Data, held on October 25, 2022.
Posted 1/4/2023 (updated 10/26/2023)
The RCORP-Evaluation & RCORP-Technical Assistance teams hosted two webinars on Strategies for Collecting RCORP Data for new Implementation 4, Psychostimulant Support 2, Behavioral Healthcare Support, and MAT Access grantees. Below you’ll find the recording and slides to access the webinar recording from our session held on December 14th.
Posted 2/7/2023 (updated 10/26/2023)
This session was held for Implementation 4 grantees preparing for their first PIMS report, but the content is applicable to all RCORP cohorts who are interested in improving their data collection and reporting strategies.
Posted 7/12/2023 (updated 11/13/2023)
Below, you’ll find the slides and recording from the June 28th, 2023 session.
Posted 12/22/2020 (updated 2/16/2024)
An overview by the American Medical Association (AMA) of the changes to coding for Evaluation and Management (E&M) services.
Posted 2/7/2023 (updated 2/20/2024)
This session was held for Implementation III grantees who are interested in learning more about how to access and utilize their recently released RCORP Data Dashboards. January Data Coordinator meeting content, which includes strategies for preventing common PIMS errors, is also covered during this session.
Posted 11/19/2019 (updated 3/25/2024)
The intersection of opioid abuse, particularly injection drug use (IDU), and HIV is well documented; in fact, IDU is the second most frequent route of HIV transmission. Injection drug use, either directly or via sexual contact with an IDU partner, accounts for one-third of the estimated AIDS cases since the beginning of the epidemic, and 18 percent of new infections in the United States.
Posted 2/9/2022 (updated 3/26/2024)
Summary of innovation abstracts that were presented at the National Academy of Medicine’s recent Stigma of Addiction Summit.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).